This trial is a safety trial of GEN3014, a new drug. The trial has two parts: a dose escalation part, which is the first time the drug will be used in humans, and an expansion part.
7 Primary · 24 Secondary · Reporting Duration: From first dose until end of Cycle 2, (each cycle is 28 days)
272 Total Participants · 5 Treatment Groups
Primary Treatment: GEN3014 (HexaBody®-CD38) · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: